132 A review of why patients with performance status 0-2 didn't receive anti-cancer treatment

The National Lung Cancer Audit (NLCA) reported in November 2023 that 79% of patients with non-small cell lung cancer (NSCLC) with stage I or II disease and a performance status (PS) of 0-2 received curative intent treatment (audit standard ≥80%), and 60% of patients with NSCLC stage IIIA, PS 0-2, received curative intent treatment. Furthermore, 61% of patients with NSCLC stage IIIB–IV, PS0-1 received systemic anticancer treatment (audit standard ≥65%). To compare against national standards, a retrospective review was performed.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Other Source Type: research